Metoclopramide for Acute Upper GI Bleeding

• Status: Not yet recruiting
• Trial end date: 2022-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The presence of blood clot in stomach limited quality of endoscopic view ,which affect successful rate of hemostatic endoscopy in patient with acute upper gastrointestinal bleeding. The study is aimed to evaluate the efficacy of metoclopramide, as pro-kinetic agent ,for gastric visualization in the patient with acute UGIB; double-blind randomized controlled trial and two centers study. The patient were randomly assigned to receive either metoclopramide (10mg) intravenously or placebo before endoscopy 30-120 min. The primary endpoint was endoscopic yield, assessed by objective gastric visualized scoring systems. Secondary end points include duration of endoscope, technical success rate, the need for second-look EGD, units of blood transfusion, length of hospital stay and 30-day rebleeding rate.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: King Chulalongkorn Memorial Hospital
• Treatments: Metoclopramide

Criteria

Inclusion Criteria:

1. Age >= 18 years

2. Active upper GI bleeding ( defined as fresh or bright red hematemesis within 24hr. or presented of blood via NG aspiration )

3. Underwent upper GI endoscopy within 12hr

4. Informed consent obtained

Exclusion Criteria:

1. Known allergy of metoclopramide

2. History of gastric or duodenal surgery

3. Known case esophageal, gastric or duodenal cancer

4. Diagnosed with advanced HIV infection (defined as CD4 cell count <200 cells/mm3 or WHO clinical stage 3 or 4)

5. Poor ambulatory status (defined as capable of only limited selfcare, confined to bed or chair more than 50% of waking hours; applied from WHO/ECOG performance stage ≥3)

6. Pregnancy or lactating

7. NG lavage was done with solution > 50 ml.